EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
May 12, 2021 16:15 ET
|
EyeGate Pharmaceuticals, inc.
- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21- -OBG: U.S. IND submission and initiation of Phase 2 dry eye study...
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors
April 01, 2021 06:55 ET
|
EyeGate Pharmaceuticals, inc.
WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory...
EyeGate Pharma Reports Full Year 2020 Financial Results and Provides Business Update
March 25, 2021 16:15 ET
|
EyeGate Pharmaceuticals, inc.
WALTHAM, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for...
EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation
February 01, 2021 06:55 ET
|
EyeGate Pharmaceuticals, inc.
- Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development - - Stephen From Elevated from Chief Executive Officer to Executive Chairman - ...
EyeGate Enters Into Agreement for $8.0 Million Private Placement
January 06, 2021 06:55 ET
|
EyeGate Pharmaceuticals, inc.
WALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for...
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
December 21, 2020 06:55 ET
|
EyeGate Pharmaceuticals, inc.
Expands Pipeline Beyond Ophthalmology with PP-001, a Clinical Stage, Best-in-Class DHODH Inhibitor PP-001 Leverages a Validated Immune Modulating Mechanism Optimized for Increased Specificity and...